501082-71-9

Basic information

• Product Name: L-Phenylalanine, O-[(2,6-dichlorophenyl)methyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl glycylglycyl-, methyl ester
• CAS NO: 501082-71-9
• Molecular Formula: C35H40Cl2N4O8
• Molecular Weight: 715.631
• Mol File: 501082-71-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: L-Phenylalanine, O-[(2,6-dichlorophenyl)methyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl glycylglycyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Phenylalanine, O-[(2,6-dichlorophenyl)methyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl glycylglycyl-, methyl ester(501082-71-9)
• EPA Substance Registry System: L-Phenylalanine, O-[(2,6-dichlorophenyl)methyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl glycylglycyl-, methyl ester(501082-71-9)

Safety Data

• Hazardous Substances Data: 501082-71-9(Hazardous Substances Data)

Upstream product

• 40298-71-3 N-tert-butoxycarbonyl-O-2,6-dichlorobenzyl-L-tyrosine 
• 61131-29-1 N-glycyl>-L-3-phenylalanine methyl ester hydrochloride 
• 106624-70-8 methyl (2S)-2-[[2-(t-butoxycarbonylamino)acetyl]amino]-3-phenylpropanoate 
• 63631-32-3 (S)-methyl 12-benzyl-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oate 
• 19240-24-5 N--L-3-phenylalanine methyl ester hydrochloride 

Downstream Products

• 521060-85-5 C₅₅H₆₆Cl₂N₆O₉ 
• 501082-91-3 2-[2-(2-{2-[2-tert-butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-acetylamino}-acetylamino)-3-phenyl-propionylamino]-4-methyl-pentanoic acid 3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl ester 
• 501083-05-2 C₅₃H₆₀Cl₂N₆O₁₀ 
• 501083-26-7 C₅₅H₆₆Cl₂N₆O₉ 
• 501083-25-6 C₅₆H₆₇Cl₂N₅O₁₀ 
• 501082-90-2 C₅₄H₆₃Cl₂N₅O₁₀ 
• 501083-31-4 C₅₂H₅₉Cl₂N₅O₁₀ 
• 501083-22-3 estrone-3-O-CH₂CO-Tyr(2,6-dichlorobenzyl)-Gly-Gly-Phe-Gly-OMe 
• 501083-32-5 C₅₁H₅₈Cl₂N₆O₉ 
• 501083-23-4 estrone-3-O-CH₂CO-Tyr(2,6-dichlorobenzyl)-Gly-Gly-Phe-Gly-NH₂ 
• 501083-43-8 C₄₉H₆₃N₅O₁₀ 

Relevant articles and documents

Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.

The linkers of estrogen-GHRPs were prepared by the combination of estradiol, estrone, TyrGlyGlyPheLeuOH, and TyrGlyGlyPheLeuOH. Their anti-osteoporosis effect was evaluated by analyzing the data, for instance the weight of the body, femur, femur ash, the content of calcium and phosphor in the femur, the content of calcium and ALP activity in the serum, obtained from the corresponding bioassay in vivo. The results indicated that the anti-osteoporosis potency for estradiol, estrone, TyrGlyGlyPheLeuOH and TyrGlyGlyPheLeuNH(2) may be totally enhanced each other via the corresponding linkers.